GSK_ Annual_Report_2021-22

139 Notes to the Standalone Financial Statements for the year ended March 31, 2022 (iv) Provision for Zinetac (Other costs) : This represents provision for incidental costs and other related costs for the Zinetac inventory pending to be destroyed. (v) Consists mainly of provisions in respect of indirect tax matters. Note 30 : Revenue from operations ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 A. Sale of products Sale of products 3190,07.67 2886,41.74 3190,07.67 2886,41.74 B. Other operating revenue Service income 13,32.13 20,67.58 Manufacturing charges recovery 13,03.40 7,60.93 Others 1,07.67 5,77.33 27,43.20 34,05.84 Total Revenue from operations (A + B) 3217,50.87 2920,47.58 C. Revenue from contracts with customers disaggregated based on geography (Refer Note 52) Revenue from the Country of Domicile- India 3209,61.60 2905,84.28 Revenue from foreign countries 7,89.27 14,63.30 3217,50.87 2920,47.58 D. Reconciliation of gross revenue with revenue from contracts with customers Gross revenue 3510,38.11 3085,55.15 Less: Trade discounts, volume rebates, etc. 320,30.44 199,13.41 Net revenue recognised from contracts with customers 3190,07.67 2886,41.74 Note 31 : Other income ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 Interest income on: Deposits with banks 41,08.56 38,61.66 Income Tax Refund 26,83.54 71,28.52 Loans 3,76.61 16.04 Others 50.49 12.56 Gain on disposal of Property, Plant and Equipment (net) 32.37 - Others 3,70.00 - 76,21.57 110,18.78 Note 32 : Cost of materials consumed ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 Cost of materials consumed 552,47.11 452,39.86 552,47.11 452,39.86 Purchases of stock-in-trade 729,44.10 823,09.06 729,44.10 823,09.06